{"id":"W4283737822","doi":"10.1164/rccm.202204-0734oc","title":"A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for <i>F508del-CFTR</i>","year":2022,"lang":"en","type":"article","venue":"American Journal of Respiratory and Critical Care Medicine","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Children's Hospital","funders":"National Center for Advancing Translational Sciences","keywords":"Ivacaftor; Medicine; Cystic fibrosis; Pharmacokinetics; Tolerability; Cystic fibrosis transmembrane conductance regulator; Adverse effect; Dosing; Internal medicine; Clinical endpoint; Pharmacodynamics; Cohort; Pharmacology; Gastroenterology; Pediatrics; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00174692,0.001224981,0.001966683,0.0003509973,0.0005431773,0.0007609552,0.0007995086,0.001132129,0.002658412],"category_scores_gemma":[0.001103082,0.0005547905,0.001430454,0.0003125306,0.0009603025,0.000886782,0.0002927124,0.003018189,0.0005351655],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007292024,"about_ca_system_score_gemma":0.001958476,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001316195,"about_ca_topic_score_gemma":0.003899917,"domain_scores_codex":[0.9993073,0.0003238138,0.00002871047,0.000112057,0.00008723263,0.0001409104],"domain_scores_gemma":[0.9989053,0.0001784278,0.0002420646,0.00008835523,0.0000935907,0.0004922728],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7224902,0.1291798,0.01425957,0.0008037771,0.001109189,0.0006040592,0.0004235204,0.001667543,0.06758367,0.0002873041,0.003746817,0.0578446],"study_design_scores_gemma":[0.4074973,0.5664269,0.0194358,0.00003246468,0.0002406119,0.0002854415,0.00007709394,0.0008135881,0.003332609,0.0001178125,0.001708307,0.00003211195],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932319,0.001167996,0.0005801525,0.0002160989,0.0001099764,0.002818631,0.001066005,0.00007011509,0.0007392089],"genre_scores_gemma":[0.9875388,0.001099888,0.002586229,0.000988832,0.0002065081,0.004378099,0.001500684,0.00002825112,0.001672694],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002658412,"threshold_uncertainty_score":0.00923872,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03333232593739176,"score_gpt":0.3837717561411313,"score_spread":0.3504394302037395,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}